Clinical Takeaway
People with PTSD and co-occurring substance use disorders who also use cannabis can still benefit meaningfully from trauma-focused treatments. Cannabis use does not appear to undermine the effectiveness of evidence-based PTSD interventions in this population. Clinicians should not withhold or delay trauma-focused care for patients simply because they are using cannabis.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis directly addresses a critical clinical gap by examining whether evidence-based PTSD treatments remain efficacious in patients with concurrent cannabis use and comorbid SUDs, populations often excluded from traditional RCTs. The findings provide essential guidance for treatment selection and outcome expectations when managing the increasingly common presentation of PTSD with polysubstance use, where cannabis use patterns may confound or modify treatment response. Understanding differential treatment efficacy across substance use profiles enables clinicians to make informed decisions about psychotherapeutic interventions in complex, real-world patient populations that represent a substantial proportion of individuals seeking PTSD care.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 While this meta-analysis addresses a clinically relevant question about trauma-focused treatment outcomes in patients with comorbid PTSD, cannabis use, and other substance use disorders, several important limitations warrant careful interpretation. The analysis draws from a subset of only four RCTs within a larger Project Harmony dataset, which constrains generalizability and statistical power for detecting meaningful differences in this complex population. Heterogeneity in cannabis use patterns (frequency, potency, route of administration), timing relative to treatment, and baseline severity of PTSD and SUD across the original trials introduces confounding that individual patient data analysis may not fully resolve. The findings should not be interpreted as definitive guidance for excluding cannabis-using patients from evidence-based trauma-focused therapies, as treatment engagement and retention often matter more than substance use status alone. In practice, clinicians should continue offering trauma-focused treatments to appropriate candidates with comorbid PTSD and cannabis use while addressing cannabis use directly in the treatment plan, monitoring response carefully, and considering integrated care